Glenmark announce FabiFlu
Glenmark Pharmaceuticals Limited has announced the introduction of Favipiravir in India. Under the brand name FabiFlu for the treatment of mild & moderate COVID-19 cases in India.
Glenmark received approval from DCGI
The Drugs Controller General of India (DCGI) given approval to Glenmark. Glenmark Pharmaceuticals drug firm has launched antiviral drug Favipiravir. It is for the treatment of patients with mild to moderate COVID-19 patients. Under the brand name FabiFlu.
Tablets at 103 rupees only
Price at ₹103 per tablet. This is a prescription-based drug. this drug will be available as a 200 mg tablet. these drugs will available At an MRP of ₹3,500 for a strip of 34 tablets. It is an oral product. The recommended dose is 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14.
The FabiFlu could be a GameChanger for COVID 19 patients
The drug will be available both through hospitals and retail channels. Dr Rommel Tickoo, Associate Director, said the drug could be a “potential game-changer”. This drug is in the form of tablets so it is easy to administrate and it is inexpensive. This tablet has to be given in the early stages. They are producing active pharmaceutical ingredients at its Ankleshwar plant. At Baddi plant, the formulation is being manufactured.
Offers a rapid reduction in 4 days
It provides a rapid reduction in viral within 4 days. And also provides faster symptomatic and radiological improvement. Favipiravir has shown clinical improvement of up to 88 per % in mild to moderate COVID-19 cases. Glenmark was the 1st company in India to receive the drug regulator’s approval. considering at least of two strips per patient. Glenmark will be able to provide FabiFlu tablets about 82,500 patients in the first month itself. FabiFlu is available to all patients who need it.